A European clinical trial found that sulthiame, a drug used in the treatment of epilepsy, reduced breathing interruptions.

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

Ovid Therapeutics (OVID) shares jumped over 40% premarket as the biopharmaceutical company reported favorable safety and tolerability results for the 7 mg dose of its OV329 epilepsy drug, while ...

Researchers found that the medication sulthiame reduced breathing interruptions and improved oxygen levels overnight in people with moderate to severe sleep apnea. The findings were published recently ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

Ovid Therapeutics Inc. (NASDAQ:OVID) said Wednesday it has raised $60 million through a private placement to support the continued development of its epilepsy drug candidate OV329, including expanding ...

Analysts are encouraged by azetukalner’s differentiated MoA and efficacy in epilepsy, as well as the lack of titration needed when prescribing the drug.

New carbidopa/levodopa labels will state that seizures linked to vitamin B6 deficiency can ...